[go: up one dir, main page]

GB2149301B - Pyridine-soluble extract - refined detoxified endotoxin composition and use - Google Patents

Pyridine-soluble extract - refined detoxified endotoxin composition and use

Info

Publication number
GB2149301B
GB2149301B GB08423993A GB8423993A GB2149301B GB 2149301 B GB2149301 B GB 2149301B GB 08423993 A GB08423993 A GB 08423993A GB 8423993 A GB8423993 A GB 8423993A GB 2149301 B GB2149301 B GB 2149301B
Authority
GB
United Kingdom
Prior art keywords
pyridine
soluble extract
detoxified endotoxin
refined detoxified
endotoxin composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB08423993A
Other versions
GB8423993D0 (en
GB2149301A (en
Inventor
John Leonard Cantrell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of GB8423993D0 publication Critical patent/GB8423993D0/en
Publication of GB2149301A publication Critical patent/GB2149301A/en
Application granted granted Critical
Publication of GB2149301B publication Critical patent/GB2149301B/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A pharmaceutical composition comprising a purified pyridine-soluble extract of a microorganism and a refined detoxified endotoxin which is effective in producing an immunological response in warm blooded animals and humans. Methods of using the composition for these purposes are also disclosed.
GB08423993A 1983-09-23 1984-09-21 Pyridine-soluble extract - refined detoxified endotoxin composition and use Expired GB2149301B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/535,037 US4663306A (en) 1983-09-23 1983-09-23 Pyridine-soluble extract-refined detoxified endotoxin composition and use

Publications (3)

Publication Number Publication Date
GB8423993D0 GB8423993D0 (en) 1984-10-31
GB2149301A GB2149301A (en) 1985-06-12
GB2149301B true GB2149301B (en) 1988-06-22

Family

ID=24132594

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08423993A Expired GB2149301B (en) 1983-09-23 1984-09-21 Pyridine-soluble extract - refined detoxified endotoxin composition and use

Country Status (23)

Country Link
US (1) US4663306A (en)
JP (1) JPS60120817A (en)
KR (1) KR870000843B1 (en)
AT (1) AT385659B (en)
AU (1) AU566234B2 (en)
BE (1) BE900650A (en)
CA (1) CA1244765A (en)
CH (1) CH664897A5 (en)
DE (1) DE3434766C2 (en)
DK (1) DK446684A (en)
ES (1) ES8608872A1 (en)
FI (1) FI843716L (en)
FR (1) FR2552326B1 (en)
GB (1) GB2149301B (en)
HU (1) HU192585B (en)
IL (1) IL73034A (en)
IN (1) IN157240B (en)
IT (1) IT1179444B (en)
NL (1) NL8402902A (en)
NO (1) NO843776L (en)
NZ (1) NZ209635A (en)
SE (1) SE8404707L (en)
ZA (1) ZA847405B (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844894A (en) * 1984-07-12 1989-07-04 Ribi Immunochem Research Inc. Method of inhibiting the onset of septicemia and endotoxemia
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US4806352A (en) * 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4929604A (en) * 1986-05-28 1990-05-29 Board Of Regents, The University Of Texas System Lipopolysaccharides of reduced toxicity and the production thereof
AU7488794A (en) * 1993-08-27 1995-03-21 Vetrepharm, Inc. Composition and method for stimulation of reproductive performance
BE1007823A3 (en) * 1993-12-10 1995-10-31 Anda Biolog Sa Use of a composition containing at least one antigen and / or one or more fragments of this antigen for obtaining a drug for treating and / or preventing cancer.
US6090385A (en) * 1993-12-10 2000-07-18 Maes; Hubert Method of treating cancer
US5976580A (en) 1995-06-07 1999-11-02 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
DE19710255A1 (en) * 1997-03-13 1998-09-17 Henkel Ecolab Gmbh & Co Ohg Use of a solution to deactivate endotoxins
CA2299548C (en) 1997-08-05 2009-12-29 Bioniche Inc. Composition and method for regulating cell proliferation and cell death
US6019985A (en) * 1998-02-27 2000-02-01 Munova Corporation Immunostimulation methods for providing disease protection in poultry
CN1230184C (en) * 1998-07-16 2005-12-07 东市郎 Prepns. for immunotherapy for cancer having bacterial somatic constituent as active ingredient
CN100445380C (en) * 1999-12-13 2008-12-24 拜昂尼科生命科学有限公司 Therapeutically useful synthetic oligonucleotides
WO2001047561A1 (en) * 1999-12-28 2001-07-05 Bioniche Life Sciences Inc. Hyaluronic acid in the treatment of cancer
NZ523535A (en) * 2000-07-11 2004-12-24 Bayer Ag Use of strains of the Parapoxvirus ovis against organ fibroses
CA2478106A1 (en) * 2002-03-05 2003-09-12 Cell-Medicine, Inc. Solidified tissue immunoadjuvant
WO2004012751A1 (en) * 2002-08-02 2004-02-12 Sumitomo Pharmaceuticals Company, Limited Bacterial cell wall skeleton component preparaion
FR2848223B1 (en) * 2002-12-09 2005-02-25 Centre Nat Rech Scient NOVEL METHOD OF ISOLATING ENDOTOXINS.
US20060127518A1 (en) * 2003-09-05 2006-06-15 Shenyang Sunbellcom Bio-Pharmaceutical Co. Red nocardia cell wall skeleton preparation process and its therapeutic use on treating cervical erosion
CA2564180A1 (en) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation containing bacterial cell wall skeleton component
EP2986303B1 (en) 2013-04-18 2020-02-26 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
US10584344B2 (en) 2014-06-17 2020-03-10 Crown Laboratories, Inc. Genetically modified bacteria and methods for genetic modification of bacteria
US11504404B2 (en) 2016-02-24 2022-11-22 Crown Laboratories, Inc. Skin probiotic formulation
EP3668957A4 (en) * 2017-08-17 2021-06-02 University of Delaware FURAN-BASED COMPOSITIONS AND THEIR MANUFACTURING PROCESSES
CA3183350A1 (en) 2020-06-23 2021-12-30 Thomas M. Hitchcock Probiotic skin formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7308450A (en) * 1972-06-20 1973-12-27
FR2269962B1 (en) * 1974-05-06 1978-02-03 Anvar
JPS58874B2 (en) * 1979-08-30 1983-01-08 株式会社 目黒研究所 Glycoprotein WENAC and its production method
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4435386A (en) * 1982-05-26 1984-03-06 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
CA1206415A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism
CA1209504A (en) * 1982-06-30 1986-08-12 John L. Cantrell Pyridine soluble extract of a microorganism
CA1206416A (en) * 1982-06-30 1986-06-24 John L. Cantrell Pyridine soluble extract of a microorganism

Also Published As

Publication number Publication date
HUT35521A (en) 1985-07-29
SE8404707L (en) 1985-03-24
GB8423993D0 (en) 1984-10-31
ES8608872A1 (en) 1986-07-16
JPS60120817A (en) 1985-06-28
SE8404707D0 (en) 1984-09-20
JPS6254775B2 (en) 1987-11-17
NL8402902A (en) 1985-04-16
DK446684A (en) 1985-03-24
DK446684D0 (en) 1984-09-19
US4663306A (en) 1987-05-05
NZ209635A (en) 1989-01-27
DE3434766A1 (en) 1986-04-30
ES536167A0 (en) 1986-07-16
ZA847405B (en) 1985-05-29
FR2552326A1 (en) 1985-03-29
AU566234B2 (en) 1987-10-15
FI843716A0 (en) 1984-09-21
IL73034A (en) 1988-11-15
FI843716L (en) 1985-03-24
AT385659B (en) 1988-05-10
NO843776L (en) 1985-03-25
AU3340084A (en) 1985-03-28
ATA302384A (en) 1987-10-15
KR870000843B1 (en) 1987-04-25
IT1179444B (en) 1987-09-16
IN157240B (en) 1986-02-15
DE3434766C2 (en) 1987-05-14
BE900650A (en) 1985-03-21
GB2149301A (en) 1985-06-12
CA1244765A (en) 1988-11-15
HU192585B (en) 1987-06-29
FR2552326B1 (en) 1988-05-13
KR850002404A (en) 1985-05-13
CH664897A5 (en) 1988-04-15
IT8448894A0 (en) 1984-09-24

Similar Documents

Publication Publication Date Title
GB2149301B (en) Pyridine-soluble extract - refined detoxified endotoxin composition and use
GB2210557B (en) Vaccine containing tumor antigens and refined detoxified endotoxin as an adjuvant.
NO175042C (en)
DE3370482D1 (en) Substituted 8-phenylxanthines
MC1626A1 (en) PROCESS FOR THE PREPARATION OF IMMUN INTERFERON
AU7757081A (en) Post expansion heat treatment of tobacco
JPS57169482A (en) Imidazopyrimidine derivative and application to medicine
NZ214652A (en) Vaccine against fasciola
AU5781886A (en) Process for the in vitro immunization of human splenocytes against tumor associated antigens
AU4482985A (en) Pyrro-1-yl-phenyl-dihydropyridazones
FR2550945B1 (en) PURIFIED ENDOTOXIN COMPOSITIONS AND THEIR PHARMACOLOGICAL APPLICATION
AU7344081A (en) Occupier adjustable invalid bed
NL194960B (en) Method for the preparation of mutant strains of Bordetella bronchiseptica and live attenuated vaccine based on it.
GR3005231T3 (en)
JPS5589232A (en) Vaccines against reo virus disease and their manufacture
GB2144129B (en) Antigens as immunostimulant adjuvants
AU558071B2 (en) Live vaccine for bovine babesiosis and method of preparation
IL63338A0 (en) Vaccine against bacterial diseases and its preparation
PT85284A (en) PROCESS FOR THE PREPARATION OF EXOCELLULAR ANTIGENIC FRACTIONS OF BORDETELLA PERTUSSIS AND VACCINE AGAINST THE CO-UELUCHE CONTAINING SUCH FRACTIONS
RO88628A2 (en) VACCINE AGAINST THE EMEA CONTAGIOUS ECTIM AND METHOD OF PREPARATION

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19970921